» Authors » Andrea Camerini

Andrea Camerini

Explore the profile of Andrea Camerini including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 68
Citations 846
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
11.
Bersanelli M, Verzoni E, Cortellini A, Giusti R, Calvetti L, Ermacora P, et al.
EClinicalMedicine . 2023 Jul; 61:102044. PMID: 37434748
Background: The prospective multicentre observational INVIDIa-2 study investigated the clinical effectiveness of influenza vaccination in patients with advanced cancer receiving immune checkpoint inhibitors (ICI). In this secondary analysis of the...
12.
Camerini A, Del Conte A, Pezzuto A, Scotti V, Facchinetti F, Ciccone L, et al.
Cancers (Basel) . 2022 Dec; 14(24). PMID: 36551561
Limited evidence is available concerning the selection criteria and the outcomes of platinum unfit newly diagnosed advanced NSCLC patients receiving single-agent chemotherapy. We retrospectively collected data on consecutive, stage IIIB-IV,...
13.
Canale M, Bisceglia I, Gallucci G, Russo G, Camerini A, Di Fusco S, et al.
Front Cardiovasc Med . 2022 Dec; 9:974123. PMID: 36505385
As cardio-oncology imposed itself as the reference specialty for a comprehensive cardiovascular approach to all patients with cancer, a more specific and careful cardiac evaluation of women entering their journey...
14.
Canale M, Camerini A, Orso F, Misuraca L, Carluccio M, Talini E, et al.
G Ital Cardiol (Rome) . 2022 Jun; 23(6):437-443. PMID: 35674034
Cardio-oncology is now part of the standard clinical approach for patients with cancer and cannot be overlooked anymore. While its scientific background is solid and its clinical relevance is well...
15.
Canale M, Turazza F, Lestuzzi C, Parrini I, Camerini A, Russo G, et al.
Front Cardiovasc Med . 2022 May; 9:920605. PMID: 35620512
[This corrects the article DOI: 10.3389/fcvm.2021.677544.].
16.
Canale M, Coviello K, Solarino G, Del Meglio J, Simonetti F, Venturini E, et al.
Front Cardiovasc Med . 2022 Mar; 9:801143. PMID: 35299980
Effective anticancer treatments have dramatically improved the outcome of patients with cancer, but cardiac toxicity reduces their clinical efficacy in a non-negligible percentage of patients. Sacubitril/valsartan is a new paradigm...
17.
Spagnoli L, Petrelli F, Fratini G, De Nisi M, Camerini A, Giusti A, et al.
Tumori . 2022 Feb; 108(6):NP5-NP10. PMID: 35168438
Introduction: Pulmonary carcinosarcoma is a rare histological subtype of non-small cell lung cancer, defined by the combination of epithelial and mesenchimal elements. Prognosis is usually dismal, with a median survival...
18.
Tibaldi C, Mazzoni F, Scotti V, Vasile E, Pozzessere D, Stasi I, et al.
Anticancer Agents Med Chem . 2021 Jul; 22(7):1278-1285. PMID: 34315390
Background: In advanced non-small-cell lung cancer, without activating mutations and with PD-L1≥50%, Pembrolizumab monotherapy is the therapeutic standard in Europe. Objective: To evaluate retrospectively the safety and efficacy of this...
19.
Canale M, Turazza F, Lestuzzi C, Parrini I, Camerini A, Russo G, et al.
Front Cardiovasc Med . 2021 Jul; 8:677544. PMID: 34222373
Cardio-oncology has achieved a pivotal role in science, but real world data on its clinical impact are still limited. A questionnaire was sent out to all cardio-oncology services across Italy...
20.
Bersanelli M, Giannarelli D, De Giorgi U, Pignata S, Di Maio M, Clemente A, et al.
J Immunother Cancer . 2021 May; 9(5). PMID: 34016723
Background: Until now, no robust data supported the efficacy, safety and recommendation for influenza vaccination in patients with cancer receiving immune checkpoint inhibitors (ICIs). Methods: The prospective multicenter observational INfluenza...